Using Vitamin B5 to Treat Inflammatory Bowel Diseases

Clinical Study of Vitamin B5 in Adjuvant Treatment of Inflammatory Bowel Disease

This study is testing if adding Vitamin B5 to the usual treatment can help people with Inflammatory Bowel Diseases feel better and achieve remission.

Quick facts

• Phase: Not applicable
• Study type: Interventional
• Enrollment: 100 (estimated)
• Ages: 18 Years to 75 Years
• Sex: All
• Sponsor: Changhai Hospital (Academic / other)
• Locations: 1 site (Shanghai)
• Trial ID: NCT05701501 on ClinicalTrials.gov

What this trial studies

This clinical study investigates the effectiveness of Vitamin B5 as an adjuvant treatment for patients with Inflammatory Bowel Diseases (IBD). Participants will be randomly assigned to receive either Vitamin B5 tablets or a placebo, alongside their standard treatment. The primary goal is to determine if Vitamin B5 can enhance the clinical remission rates and overall treatment outcomes for IBD patients. The study aims to gather comprehensive medical history data from participants to assess the treatment's impact accurately.

Who should consider this trial

Good fit: Ideal candidates include individuals diagnosed with IBD who meet the inclusion criteria and are willing to participate.

Not a fit: Patients with severe complications from IBD or other significant health issues may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could improve remission rates and overall management of IBD for patients.

How similar studies have performed: While the use of Vitamin B5 in this context is novel, other studies exploring vitamin supplementation in IBD have shown varying degrees of success.

Eligibility criteria

Inclusion Criteria:

* Patients diagnosed with IBD according to the consensus on the diagnosis and treatment of inflammatory bowel disease (Beijing, 2018, DOI:10.19538/j.nk2018090106);
* Have complete medical history data;
* Volunteer to participate in this clinical trial and sign the informed consent form.

Exclusion Criteria:

* Hemophilic patients;
* There are abdominal abscesses, toxic megacolon, fulminant colitis, partial colectomy, or total colectomy;
* Other autoimmune diseases, hematological diseases, tumors, acute infection, severe liver and kidney insufficiency, serious diseases such as severe anemia, neutropenia, heart failure, organic heart disease, hepatitis B, liver cirrhosis, kidney disease and mental diseases;
* Take calcium pantothenate preparation in recent 3 months;
* Have a history of abuse of psychoactive substances;
* Pregnant or lactating women, or plan to be pregnant in the next 6 months;
* Nervous system diseases: such as Alzheimer's disease, stroke, Parkinson's disease;
* Participate in other clinical trials in the past 6 months;
* Incomplete medical record information (including gender, age, diagnosis information, colonoscopy results, pathological diagnosis results and other demographic data)

Where this trial is running

Shanghai

• Changhai Hospital — Shanghai, China (Recruiting)

Study contacts

• Principal investigator: Zhaoshen Li, MD — Changhai Hospital
• Study coordinator: Zhaoshen Li, PhD, MD

Conditions Inflammatory Bowel Diseases; Vitamin B5,treatment